source
- GSK to launch large trial testing shingles vaccine’s potential to reduce Alzheimer’s riskGSK announced it will conduct a large-scale clinical study to evaluate whether the shingles vaccine can lower the risk of developing Alzheimer’s disease. The move follows observations from analyses…
- GSK drops chronic cough drug camlipixant after mixed Phase 3 resultsGSK announced it will stop investing in camlipixant for refractory chronic cough after the drug failed to meet key endpoints in a late-stage trial. The company had run two Phase 3 studies, CALM-1…